ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DEP114

A development code.

Its studies are mostly in Rhinitis, Allergic, led by EMS.

Furthest: phase 3, since Feb 9, 20242 company-led studies, 2 open or runningNext primary completion: Dec 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
EMS22 open or runningphase 3since Feb 9, 2024Feb 9, 2024Dec 2028phase 3 · NCT07835074

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 9, 2024First study: phase 3 study in Rhinitis, AllergicFirst studyNCT06272409 · 318 planned
  2. Sep 15, 2026Phase 3 study in Persistent Allergic RhinitisNCT07835074 · 316 planned

Ahead

  1. Dec 2028Primary completion: phase 3 study in Persistent Allergic RhinitisNCT07835074

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07835074Persistent Allergic Rhinitis3Not yet recruitingDec 2028316
NCT06272409Rhinitis, Allergic3Not yet recruitingMar 15, 2025318

How it is read

Names in the registry

  • “DEP114”, 2 entries

Codes read as this program: DEP114.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.